Michael Niggel

An IDEAL Initiative in Lupus Research: Q&A With Dr. Stacie J. Bell, Lupus Therapeutics, and Dr. Teodora Staeva, Lupus Research Alliance 

|
Can diet make a difference in lupus?

Could diet and gut health impact the lived experience of lupus? This intriguing question lies at the heart of a groundbreaking initiative by Lupus Therapeutics (LT), the clinical research affiliate of the Lupus Research Alliance (LRA), called IDEAL (Investigate Dietary Approaches for Lupus). IDEAL will provide up to two grants for pilot clinical studies evaluating … An IDEAL Initiative in Lupus Research: Q&A With Dr. Stacie J. Bell, Lupus Therapeutics, and Dr. Teodora Staeva, Lupus Research Alliance 

On “Endpoints Clinical Trials Day,” Lupus Therapeutics EVP  Expresses Optimism About the Current State of Lupus Research

|

Today is “Endpoints Clinical Trials Day,” hosted by international biopharma news outlet Endpoints News. The day features a series of discussions on the latest trends in clinical trials in the US and abroad, the regulatory environment, and how industry and others are helping to improve trial strategies of the future. These include plans to ensure … On “Endpoints Clinical Trials Day,” Lupus Therapeutics EVP  Expresses Optimism About the Current State of Lupus Research

Lupus Therapeutics Statement on Phase 3 PHOENYCS GO Positive Data In Moderate-To-Severe Systemic Lupus

|
News from ACR Convergence 2024

Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance (LRA), is encouraged by the positive Phase 3 PHOENYCS GO data reported by UCB and Biogen during ACR Convergence 2024. Study sponsors provided a detailed analysis of the pivotal trial to evaluate the efficacy and safety of dapirolizumab pegol (DZP) in patients with moderate-to-severe … Lupus Therapeutics Statement on Phase 3 PHOENYCS GO Positive Data In Moderate-To-Severe Systemic Lupus

ACR Released a Summary of the 2024 ACR Guideline for the Screening, Treatment, and Management of Lupus Nephritis

|
News from ACR Convergence 2024

The American College of Rheumatology (ACR) released a summary of the 2024 ACR Guideline for the Screening, Treatment, and Management of Lupus Nephritis during ACR Convergence 2024. “This is the College’s first lupus nephritis guideline since 2012 and provides evidence-based, expert guidance for the condition in adults and children.” Lupus Therapeutics, clinical affiliate of the Lupus … ACR Released a Summary of the 2024 ACR Guideline for the Screening, Treatment, and Management of Lupus Nephritis

Lupus Research Alliance Announces Lupus Research Highlights at ACR Convergence 2024

|
Announcing LRA-supported research studies at ACR

Two reports by Lupus Therapeutics, the clinical affiliate of the LRA, and the Lupus Clinical Investigators Network (LuCIN), on promoting equity in lupus clinical trials, and identifying trial barriers and solutions The Lupus Research Alliance (LRA), the largest private funder of lupus research worldwide, today announced that 34 presentations, including research funded by the organization … Lupus Research Alliance Announces Lupus Research Highlights at ACR Convergence 2024

Lupus Research Alliance Launches Two Major Initiatives to Increase Participation of Underrepresented Minorities in Lupus Clinical Trials and Research

|

The Lupus Research Alliance (LRA) and its clinical affiliate Lupus Therapeutics (LT) announced two major initiatives to address underrepresentation of minorities in clinical trials and in the scientific research profession: Project CHANGE by LT and the Diversity in Lupus Research Program. The organization has tackled these disparities for decades and now embarks on this highly … Lupus Research Alliance Launches Two Major Initiatives to Increase Participation of Underrepresented Minorities in Lupus Clinical Trials and Research